CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer

Molecular Medicine Reports

Volumn 1, Issue 2, 2008, Pages 257-262

  Wedel, Steffen A ^a   Raditchev, Ivaylo N ^a   Jones, Jon ^a   Juengel, Eva ^a   Engl, Tobias ^a   Jonas, Dietger ^a   Blaheta, Roman A ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Chemokines; Kattan; Prognosis; Prostate cancer; Prostate specific antigen

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; POSTOPERATIVE PERIOD; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 67650374145     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837, 2002.
2. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E and Peled A: Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18: 1240-1242, 2004. (Pubitemid 39561563)
3. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK and Taichman RS: Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20: 318-329, 2005.
4. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, Jonas D and Blaheta RA: Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 78: 1784-1793, 2006. (Pubitemid 43295576)
5. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD and Zhang J: Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67: 3646-3653, 2007. (Pubitemid 46762149)
6. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ and Taichman RS: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89: 462-473, 2003. (Pubitemid 36648768)
7. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD and Cher ML: CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66: 32-48, 2006. (Pubitemid 43005947)
8. Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D and Blaheta RA: CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 8: 290-301, 2006.
9. Carlo ED, Magnasco S, D'Antuono T, Tenaglia R and Sorrentino C: The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21. Prostate 67: 1070-1080, 2007. (Pubitemid 46983336)
10. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J and Scardino P; Transatlantic Prostate Group: Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194, 2006. (Pubitemid 44658482)
11. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE and Holmberg L; Scandinavian Prostate Cancer Group Study No. 4: Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99: 526-532, 2007.
12. Chun FK, Karakiewicz PI, Briganti A, Walz J, Kattan MW, Huland H and Graefen M: A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 99: 794-800, 2007. (Pubitemid 46439569)
13. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT and Kattan MW: A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 7: 141-146, 2002. (Pubitemid 41128660)
14. Arya M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J and Williamson M: The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 4: 291-303, 2004. (Pubitemid 40189442)
15. Shen H, Schuster R, Lu B, Waltz SE and Lentsch AB: Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66: 1721-1728, 2006. (Pubitemid 44893898)
16. Nagpal ML, Davis J and Lin T: Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta 1762: 811-818, 2006. (Pubitemid 44403048)